Metabolic disease
-
Innovent Presents Multiple Research Results from General Biomedicine Pipeline at ADA 85th Scientific Sessions
Innovent Biologics will present at the ADA’s 85th Scientific Sessions, unveiling research on its pipeline for metabolic disease. Key highlights include IBI3030, a novel anti-PCSK9 antibody conjugate, and promising results on mazdutide, a dual GCG/GLP-1 receptor agonist. Mazdutide data will focus on liver fat reduction, MASH and fibrosis improvement, and uric acid reduction. The presentation will feature results from preclinical studies and investigator-initiated trials, pointing to Innovent’s focus on innovative metabolic disease therapies.
